XCELL BIOLOGIX™ is a global regenerative medicine company focused on innovative amnion derived technologies that could disrupt traditional painful and expensive treatment options for tissue regeneration and healing of chronic wounds and severe burns. On November 15, 2017, XCELL BIOLOGIX™ signed an exclusive worldwide licensing agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM), a research institute affiliated with Wake Forest School of Medicine, for development and commercialization rights for novel amnion derived technologies shown to accelerate wound closure and re-epithelialization for the protection, healing and repair of chronic wounds and severe burns. The company is rapidly building a portfolio of unique patented regenerative treatment product candidates to improve patients’ outcomes along with reducing pain and lowering costs. Founded in 2015 by Bruce Anderson and Steve Anderson of Kennesaw, Georgia and Longboat Key, Florida respectively, the company has more than 70 years’ global experience developing, manufacturing, processing and commercializing more than 20 implantable human cardiovascular and orthopedic tissues as well as Class II and III medical devices. XCELL BIOLOGIX™ was formed in Florida and is headquartered in suburban Atlanta, Georgia.